# Predictors of statin intolerance in primary care using real-world data

*Shagoofa Rakhshanda[1], Jitendra Jonnagaddala[2, 3, *], Siaw-Teng Liaw[1], Joel Rhee[2] and Kerry-Anne Rye[4]*

[1] School of Population Health, UNSW Sydney, NSW 2052 Australia

[2] Discipline of General Practice, School of Clinical Medicine, UNSW Sydney, NSW 2052 Australia

[3] SREDH Consortium, Sydney, Australia

[4] School of Biomedical Sciences, UNSW Sydney, NSW 2052 Australia

*\* Corresponding author*

Shagoofa Rakhshanda, s.rakhshanda@unsw.edu.au; ORCID: 0000-0001-9172-7042

Jitendra Jonnagaddala, jitendra.jonnagaddala@unsw.edu.au; ORCID: 0000-0002-9912-2344

Siaw-Teng Liaw, siaw@unsw.edu.au; ORCID: 0000-0001-5989-3614

Joel Rhee, J.Rhee@unsw.edu.au; ORCID: 0000-0002-5233-2758

Kerry-Anne Rye, k.rye@unsw.edu.au; ORCID: 0000-0002-9751-917X

# Abstract

**Objective:** The objective of this study was to explore the predictors of statin intolerance in the primary and secondary prevention of CVD among patients in the first two years after the date of first prescription using real-world data.

**Methods:** This study used the Electronic Practice Based Research Network Linked Dataset. An algorithm, which considered the muscle symptoms and creatinine kinase of patients, was used to identify statin intolerant patients. The R software was used for all analyses. Descriptive and multivariate logistic regression analyses were performed along with sensitivity analysis which was done using the Akaike Information Criterion model selection method.

**Results:** Overall, 4,016 patients accounting for 60,873 visits met the selection criteria. About 3.5% of the patients were statin intolerant. After adjusting for all other variables, statin intolerance was positively associated with gender (AOR 1.5, 95% CI 1.0 – 2.2), SEIFA index (AOR 3.8, 95% CI 2.3 – 6.7), employment status (AOR 2.4, 95% CI 1.1 – 5.7), and comorbidities (AOR 7.0, 95% CI 2.2 – 19.0). A similar direction of associations was seen for the exposures of the model from the sensitivity analysis and the regression model. However, since the unrecorded employment status showed a positive association, the sensitivity analysis suggests that the relationship may be influenced by residual confounding or information bias, indicating that this finding should be interpreted with caution.

**Conclusion:** Statin intolerance within the diverse community represented in the dataset is driven by gender, employment status, area-based social advantage and disadvantage index, and comorbidities.

**Keywords:** Statin, intolerance, primary care, real-world data, cardiovascular diseases

**Word count in abstract:** 244

**Word count in full text:** 2,734

# 1. Introduction

Statins are a group of lipid-modifying drugs that are prescribed as primary and secondary prevention of cardiovascular diseases (CVDs) in Australia (1). They are commonly used as the first line of pharmacological therapy for CVD risk management, and are prescribed to 30% of Australian patients aged more than 55 years (2, 3). Although statins are normally quite well tolerated, statin intolerance can occur partially in about 15% patients, and complete statin intolerance can occur in about 5% patients (4, 5). Statin intolerance is defined differently by different scientific groups, trialists, and societies (6). However, it is commonly known as the inability to tolerate statin therapy due to adverse effects, most notably statin-associated muscle symptoms (SAMS) (6, 7). Symptoms of statin intolerance include weakness, muscle aches (myalgia), or cramps, myopathy, memory loss and rhabdomyolysis. Some of the other symptoms include sleep disturbances, peripheral neuropathy, diabetes mellitus, erectile dysfunction, and increased creatinine kinase (4, 5, 8). Statin intolerance may effect statin adherence which can result in increased risk of CV events (9, 10).

The literature suggests that there are a range of demographic and clinical factors that affect statin intolerance, such as age, gender, statin intensity, and comorbidities (11, 12). It is found that older age, female gender, prescription of higher intensity statins and burden of more than one comorbidity are strongly associated with statin intolerance (4, 13). However, these findings may vary based on the study population and methodology. Furthermore, studies also found that pharmacogenetic and immunogenetic factors, such as LILRB5 variants and HLA associations, are also potential predictors for statin intolerance (14, 15, 16). Additional reviews discuss clinical risk factors such as hypothyroidism, vitamin D deficiency, renal impairment, and interactions with CYP3A4 inhibitors, all of which can contribute to muscle-related adverse events or mimic statin intolerance (12, 17). While diabetes mellitus is a symptom of statin intolerance, it is also a factor that may lead to statin intolerance (18).

Moreover, one of the substantial contributors to reported statin intolerance is found to be the nocebo/drucebo effect (6, 19). In such cases, patient expectation and awareness can influence and impact the reported muscle symptoms or other symptoms of statin intolerance (20, 21). This is often caused by the negative representation of statins by the media, close associates, and other sources, and can be resolve upon statin rechallenge or dose adjustments (22). As such, the prevalence of statin intolerance is often over estimated. However, identification of

statin intolerant patients can be difficult not only due to this phenomenon, but also because of

the variability in the definition of statin intolerance (19, 23). These considerations are crucial

for interpreting the prevalence of statin intolerance and for designing management pathways

that maximize adherence and cardiovascular risk reduction.

Statin intolerance is a clinically significant barrier to lipid management. Identifying

predictors of statin intolerance can help in recognizing patients at high risk, and it may inform

personalized management strategies (such as statin rechallenge, dosing modifications, or

alternative therapies) (24, 25). Predictors can facilitate risk stratification and shared decision-

making. It may also support evidence-based care to reduce cardiovascular risk while

maintaining drug tolerability (26). As such identifying predictors of statin intolerance is

crucial for optimizing lipid-lowering therapies, reducing cardiovascular risk, and maintaining

quality of life. The predictors encompass demographic, clinical, pharmacokinetic/genetic, and

psychosocial dimensions, and understanding these factors supports risk stratification,

personalized rechallenge approaches, and informed use of alternative therapies. As evidence

continues to advance, incorporating validated predictors of statin intolerance will be essential

for improving patient outcomes and guiding clinical guidelines. Therefore, the objective of

this study was to explore the predictors of statin intolerance in the primary and secondary

prevention of CVD among patients in the first two years after the date of first prescription

using real-world data.

## 2.  Methods

### 2.1 Data source:

The dataset used for this study was a comprehensive electronic health records (EHR), the

Electronic Practice Based Research Network (ePBRN) Linked Dataset, which is derived from

general practice facilities in southwest Sydney (SWS) local health district (LHD). The dataset

contains information about 249,345 patients spread across 11 general practitioner sites, who

had at least one visit between 2012 to 2019 (27, 28).

There are 76 tables in the ePBRN dataset, of which 39 tables were sourced from Best

Practice, and 37 were sourced from Medical Director. This study required a selection of data

on statin intolerance from these tables to identify patients with relevance and precision. For this, 6 tables (Patients, Visits, Visit Reason, Current Rx, Careplan Goal and Past History) and 5 tables (Patients, History, Diagnosis, Consultations and Prescription) were selected to extract data on patient diagnosis, conditions, visit details, and demographics from Best Practice and Medical Directors respectively.

## 2.2 Selection criteria

For this study, a Master table was developed consisting of patients who were prescribed statins at an index date (date when the patient was prescribed a statin for the first time). The included patients were those who were active patients (with three or more visits for any reason during the observation period of 2 years), were 18 years old or above at index date, did not have any history of statin prescription before index date. The excluded patients were those who did not survive during the observation period, and those who did not have any recorded gender or birth year and were more than 80 years old. Patients who suffered any CVD events before the index date or during the observation period were also excluded.

## 2.3 Outcome

Following the selection of patients who met the eligibility criteria, we used an algorithm to identify statin intolerant patients. The methodology for the identification of statin intolerant patients in this study is shown in **Figure 1**.

**Figure 1:** Overview of the identification of statin intolerant patients

CK: Creatine kinase

* The threshold for creatine kinase (CK) was different for patients with and without muscle symptoms

## 2.4 Exposures

Patients who were prescribed any type of statins (atorvastatin, rosuvastatin, simvastatin, pravastatin, or fluvastatin), under any brand name, were included in this study. The list of statin brand names included in the ePBRN dataset is provided in **Supplement 1**.

## 2.5 Covariates

The covariates for this study included patient demographics such as age (characterized as "<30", "30-39", "40-49", "50-59", "60-69" and "≥70"), gender, ethnicity, and employment status. The area-based social advantage and disadvantage index, as classified by the Socio-Economic Indexes for Australia (SEIFA) 2021 Index of Relative Socio-Economic Advantage and Disadvantage (IRSAD), based on suburbs and localities was also included as a covariate (29). Other covariates included health- and statin-related factors, such as smoking status, intensity of statin at index date, type of statin at index date, number of different types of statins used during the first two years, change in the intensity of statins used between the index date and last visit in two years, number of medications other than statins (polypharmacy) and the number of morbidities other than CVD (comorbidities). The intensity of statins was classified according to **Supplement 2**. The categories for polypharmacy included anti-diabetic drugs, anti-hypertensive drugs, anti-coagulant drugs and others. The categories for comorbidities included diabetes, hypertension, chronic respiratory disease, cancer, stroke, blood clots and Parkinson's disease.

## 2.6 Statistical analyses

At first, descriptive analyses of statin tolerance and intolerance were performed based on all covariates. To examine the association of statin intolerance with various factors, a multivariate logistic regression analysis was used via a backwards stepwise approach (30, 31). A bootstrap simulation approach (32, 33) with 1000 simulations was used to confirm the selection of the statistically significant predictor variables. The model's assumptions of regression were checked, and the predictors of statin intolerance was presented as OR and

95% CIs. All analyses were performed with R software. The Akaike Information Criterion
(AIC) model selection method (MASS package of the R) was used to perform the sensitivity
analysis that guides the addition and removal of predictor variables from a statistical model.
It implements stepwise algorithm that assesses competing sub-models and retains the one
with minimum AIC (34, 35, 36).

## 2.7 Ethical approval

This study and the use of data from ePBRN was approved by the UNSW Human Research
Ethics Advisory Panel (HC230066; 23 June 2023).

# 3.  Results

## 3.1  Patient selection

In the ePBRN dataset, from a total cohort of 249,345 patients accounting for 3,103,072 visits,
18,377 patients accounting for 110,147 visits were prescribed statins. After excluding patients
based on the exclusion criteria (14,361 patients with 49,274 visits), 4,016 patients with
60,873 visits were included for analysis. The details of patient selection process are shown in
**Figure 2.**

**Figure 2:** Selection of eligible patients

## 3.2  Descriptive characteristics

About 3.5% of the patients were statin intolerant. The majority of the intolerant patients were
aged 60–69 years (30.7%) and 50–59 years (28.6%), representing the two most prevalent age
groups **(Table 1)**. More than half of the intolerant patients were females (56.4%). Most of the
intolerant patients were non-Aboriginals and/or Torres Strait Islanders (90.0%) with the

largest proportion from SEIFA IRSAD category 8 (61.4%). The employment status was not

recorded for 60.0% and 11.5% of the statin intolerant patients. Nearly half of the intolerant

patients were smokers (46.4%), and the other half were non-smokers (45.0%). At the index

date, 47.1% of intolerant patients were prescribed atorvastatin, and 68.6% received it at a

moderate intensity dosage. Over the two years of observation period, there was no change in

statin for 91.4% intolerant patients, and no change in statin intensity for 90.0% intolerant

patients. About 66.4% patients were concurrently taking one additional drug alongside statin.

Majority of the statin intolerant patients presented with one (42.1%) or no (40.0%) additional

comorbid conditions besides CVD.

**Table 1:** Characteristics of patients, stratified by tolerance status (N = 4,016)

| Variable | Total (N = 4,016) | Statin intolerance status | | P-value |
| --- | --- | --- | --- | --- |
| | | Intolerant (n = 140) | Tolerant (n = 3,876) | |
| *Socio-economic and demographic factors* | | | | |
| Age in years [mean (SD)] | 58.70 (10.90) | 61.30 (10.5) | 58.60 (10.90) | < 0.01 |
| Age in years [n (%)] | | | | |
|    < 30 | 22 (0.55) | < 5 | 22 (0.57) | |
|    30 – 39 | 164 (4.08) | 4 (2.86) | 160 (4.13) | |
|    40 – 49 | 608 (15.14) | 15 (10.71) | 593 (15.30) | |
|    50 – 59 | 1,269 (31.60) | 40 (28.57) | 1,229 (31.71) | 0.063 |
|    60 – 69 | 1,232 (30.68) | 43 (30.71) | 1,189 (30.68) | |
|    ≥ 70 | 721 (17.95) | 38 (27.14) | 683 (17.62) | |
| Gender | | | | |
|    Male | 2,023 (50.37) | 60 (42.86) | 1,963 (50.64) | |
|    Female | 1,990 (49.55) | 79 (56.43) | 1,911 (49.30) | < 0.01 |
|    Other | < 5 | < 5 | < 5 | |
| Ethnicity | | | | |
|    Non-ATSI | 3,038 (75.65) | 126 (90.00) | 2,912 (75.13) | |
|    ATSI | 36 (0.90) | < 5 | 36 (0.93) | < 0.01 |
|    Not Recorded | 942 (23.46) | 14 (10.00) | 928 (23.94) | |
| SEIFA IRSAD category (decile) | | | | |
|    1 | 726 (18.08) | 19 (13.57) | 707 (18.24) | |
|    2 | 407 (10.13) | < 5 | 403 (10.40) | |
|    3 | 607 (15.11) | < 5 | 605 (15.61) | |
|    4 | 1,073 (26.72) | 29 (20.71) | 1,044 (26.93) | < 0.001 |
|    8 | 1,202 (29.93) | 86 (61.43) | 1,116 (28.79) | |
|    9 | < 5 | < 5 | < 5 | |
| Employment status | | | | |
|    Unemployed | 264 (6.57) | 8 (5.71) | 256 (6.60) | < 0.05 |

| | | | | |
|---|---|---|---|---|
| Employed | 697 (17.36) | 17 (12.14) | 680 (17.54) | |
| Retired and/or pensioner | 568 (14.14) | 31 (22.14) | 537 (13.85) | |
| Not recorded | 2,487 (61.93) | 84 (60.00) | 2,403 (62.00) | |

***Health related factor***

Smoking status

| | | | | |
|---|---|---|---|---|
| Non-smoker | 1,891 (47.09) | 63 (45.00) | 1,828 (47.16) | |
| Smoker | 1,646 (40.99) | 65 (46.43) | 1,581 (40.79) | 0.433 |
| Ex-smoker | 10 (0.25) | < 5 | 10 (0.26) | |
| Not recorded | 469 (11.68) | 12 (8.57) | 457 (11.79) | |

***Statin related factors***

Statin intensity at index date

| | | | | |
|---|---|---|---|---|
| High | 853 (21.24) | 37 (26.43) | 816 (21.05) | |
| Moderate | 2,946 (73.36) | 96 (68.57) | 2,850 (73.53) | 0.311 |
| Low | 217 (5.40) | 7 (5.00) | 210 (5.42) | |

Statin type at index date

| | | | | |
|---|---|---|---|---|
| Atorvastatin | 1,887 (46.99) | 66 (47.14) | 1,821 (46.98) | |
| Rosuvastatin | 1,255 (31.25) | 46 (32.86) | 1,209 (31.19) | |
| Simvastatin | 681 (16.96) | 19 (13.57) | 662 (17.08) | 0.580 |
| Fluvastatin | 14 (0.35) | < 5 | 14 (0.36) | |
| Pravastatin | 179 (4.46) | 9 (6.43) | 170 (4.39) | |

Number of statin types

| | | | | |
|---|---|---|---|---|
| 1 | 3,585 (89.27) | 128 (91.43) | 3,457 (89.19) | |
| 2 | 414 (10.31) | 12 (8.57) | 402 (10.37) | 0.774 |
| 3 | 15 (0.37) | < 5 | 15 (0.39) | |
| 4 | < 5 | < 5 | < 5 | |

Change in statin intensity

| | | | | |
|---|---|---|---|---|
| No change | 3,514 (87.5) | 126 (90.00) | 3,388 (87.41) | |
| High to Moderate | 109 (2.71) | 4 (2.86) | 105 (2.71) | |
| High to Low | < 5 | < 5 | < 5 | |
| Moderate to High | 289 (7.20) | 9 (6.43) | 280 (7.22) | 0.807 |
| Moderate to Low | 27 (0.67) | < 5 | 26 (0.67) | |
| Low to High | 9 (0.22) | < 5 | 9 (0.23) | |
| Low to Moderate | 65 (1.62) | < 5 | 65 (1.68) | |

Number of polypharmacy [1]

| | | | | |
|---|---|---|---|---|
| 1 [2] | 238 (5.93) | < 5 | 238 (6.14) | |
| 2 | 2,632 (65.54) | 93 (66.43) | 2,539 (65.51) | |
| 3 | 1,008 (25.10) | 40 (28.57) | 968 (24.97) | < 0.001 |
| 4 | 131 (3.26) | 5 (3.57) | 126 (3.25) | |
| 5 | 7 (0.17) | < 5 | 5 (0.13) | |

Number of comorbidities [3]

| | | | | |
|---|---|---|---|---|
| None | 2,558 (63.70) | 56 (40.00) | 2,502 (64.55) | |
| 1 | 1,097 (27.32) | 59 (42.14) | 1,038 (26.78) | < 0.001 |
| 2 | 333 (8.29) | 19 (13.57) | 314 (8.10) | |
| ≥ 3 | 28 (0.70) | 6 (4.29) | 22 (0.57) | |

[1] The categories for polypharmacy included anti-diabetic drugs, anti-hypertensive drugs, anti-
coagulant drugs and other drugs;

[2] The number of polypharmacy = 1 are the people who are only on a statins;

[3] The categories for comorbidities included diabetes, hypertension, chronic respiratory

disease, cancer, stroke, blood clots and Parkinson's disease;

ATSI: Aboriginals and Torres Strait Islanders; SEIFA IRSAD: Socio-Economic Indexes for

Areas Index of Relative Socio-Economic Advantage and Disadvantage

## 3.3   Factors effecting statin intolerance

**Table 2** shows the univariate and multivariate logistic regression analysis for factors

associated with statin intolerance. After adjusting for all other variables, the factors that were

positively associated with statin intolerance were gender (AOR 1.5, 95% CI 1.0 – 2.2),

SEIFA index (AOR 3.8, 95% CI 2.3 – 6.7), employment status (AOR 2.4, 95% CI 1.1 – 5.7),

and comorbidities (AOR 7.0, 95% CI 2.2 – 19.0). Patients who were females, those from

SIEFA IRSAD category 8, those who did not have any recorded employment status, and

those with 3 or more comorbidities beside CVDs had about 50%, 280%, 140%, and 600%

higher odds of statin intolerance, respectively, compared to the reference categories.

However, the "not recorded" status of employment cannot be interpreted as a biological effect

since it represents missing clinical information rather than a true exposure.

 **Table 2:** Univariate and Multivariate logistic regression analysis for factors associated with medication tolerance ($N = 4,016$)

| Factors | n (%) | Unadjusted Odds ratio (95% CI) | p-value | Adjusted Odds ratio (95% CI) | p-value |
|---|---|---|---|---|---|
| ***Socio-economic and demographic factors*** | | | | | |
| Age (years) | | | | | |
| ≤ 65 | 2,883 (71.79) | *Reference* | | *Reference* | |
| > 65 | 1,133 (28.21) | 1.73 (1.22 – 2.44) ** | < 0.01 | 1.37 (0.93 – 2.00) | 0.108 |
| Gender | | | | | |
| Male | 2,023 (50.37) | *Reference* | | *Reference* | |
| Female | 1,990 (49.55) | 0.74 (0.52 – 1.04) | 0.083 | 1.50 (1.03 – 2.19) * | < 0.05 |
| Other | < 5 | 12.10 (0.56 – 127.55) * | < 0.05 | 51.31 (1.83 – 1471.56) ** | < 0.01 |
| Ethnicity | | | | | |
| Non-ATSI | 3,038 (75.65) | *Reference* | | *Reference* | |
| ATSI | 36 (0.90) | 0.00 (NA) | 0.973 | 0.00 (NA) | 0.992 |
| Not recorded | 942 (23.46) | 0.35 (0.19 – 0.59) *** | < 0.001 | 0.63 (0.32 – 1.15) | 0.152 |
| SEIFA IRSAD category (decile) | | | | | |
| 1 | 726 (18.08) | *Reference* | | *Reference* | |
| 2 | 407 (10.13) | 0.37 (0.11 – 0.99) | 0.072 | 0.53 (0.15 – 1.47) | 0.264 |
| 3 | 607 (15.11) | 0.12 (0.02 – 0.43) ** | < 0.01 | 0.24 (0.04 – 0.97) | 0.076 |
| 4 | 1,073 (26.72) | 1.03 (0.58 – 1.89) | 0.912 | 1.07 (0.58 – 2.03) | 0.831 |
| 8 | 1,202 (29.93) | 2.87 (1.77 – 4.89) *** | < 0.001 | 3.80 (2.26 – 6.75) *** | < 0.001 |
| 9 | < 5 | 0.00 (NA) | 0.985 | 0.00 (NA) | 0.999 |
| Employment status | | | | | |
| Unemployed | 264 (6.57) | *Reference* | | *Reference* | |
| Employed | 697 (17.36) | 0.80 (0.35 – 1.98) | 0.608 | 1.12 (0.46 – 2.97) | 0.807 |
| Retired and/or pensioner | 568 (14.14) | 1.85 (0.88 – 4.37) | 0.129 | 2.04 (0.91 – 5.12) | 0.101 |
| Not recorded | 2,487 (61.93) | 1.12 (0.57 – 2.53) | 0.766 | 2.36 (1.11 – 5.73) * | < 0.05 |

| *Health related factor* | | | | | |
|---|---|---|---|---|---|
| **Smoking status** | | | | | |
| Non-smoker | 1,891 (47.09) | *Reference* | | *Reference* | |
| Smoker | 1,646 (40.99) | 1.19 (0.84 – 1.70) | 0.327 | 1.34 (0.92 – 1.97) | 0.132 |
| Ex-smoker | 10 (0.25) | 0.00 (NA) | 0.979 | 0.00 (NA) | 0.996 |
| Not recorded | 469 (11.68) | 0.76 (0.39 – 1.37) | 0.394 | 0.86 (0.42 – 1.64) | 0.658 |
| *Statin related factors* | | | | | |
| **Statin intensity at index date** | | | | | |
| Moderate | 2,946 (73.36) | *Reference* | | *Reference* | |
| High | 853 (21.24) | 1.35 (0.90 – 1.96) | 0.132 | 1.41 (0.88 – 2.22) | 0.140 |
| Low | 217 (5.40) | 0.99 (0.41 – 2.01) | 0.979 | 1.11 (0.39 – 2.82) | 0.835 |
| **Statin type at index date** | | | | | |
| Atorvastatin | 1,887 (46.99) | *Reference* | | *Reference* | |
| Rosuvastatin | 1,255 (31.25) | 1.05 (0.71 – 1.54) | 0.804 | 0.99 (0.65 – 1.51) | 0.971 |
| Simvastatin | 681 (16.96) | 0.79 (0.46 – 1.30) | 0.377 | 0.80 (0.43 – 1.43) | 0.466 |
| Fluvastatin | 14 (0.35) | 0.00 (NA) | 0.975 | 0.00 (NA) | 0.995 |
| Pravastatin | 179 (4.46) | 1.46 (0.67 – 2.84) | 0.298 | 1.78 (0.70 – 4.11) | 0.199 |
| **Number of statin types** | | | | | |
| 1 | 3,585 (89.27) | *Reference* | | *Reference* | |
| 2 | 414 (10.31) | 0.81 (0.42 – 1.41) | 0.482 | 1.05 (0.51 – 1.99) | 0.885 |
| 3 | 15 (0.37) | 0.00 (NA) | 0.974 | 0.00 (NA) | 0.995 |
| 4 | < 5 | 0.00 (NA) | 0.990 | 0.00 (NA) | 0.998 |
| **Change in statin intensity** | | | | | |
| No change | 3,514 (87.5) | *Reference* | | *Reference* | |
| Low to moderate | 65 (1.62) | 0.00 (NA) | 0.977 | 0.00 (NA) | 0.989 |
| Low to high | 9 (0.22) | 0.00 (NA) | 0.991 | 0.00 (NA) | 0.996 |
| Moderate to low | 27 (0.67) | 1.03 (0.06 – 4.92) | 0.974 | 1.47 (0.08 – 8.13) | 0.717 |
| Moderate to high | 289 (7.20) | 0.86 (0.40 – 1.62) | 0.677 | 1.15 (0.52 – 2.30) | 0.703 |
| High to low | < 5 | 0.00 (NA) | 0.995 | 0.00 (NA) | 0.998 |
| High to moderate | 109 (2.71) | 1.02 (0.31 – 2.49) | 0.963 | 1.06 (0.29 – 2.98) | 0.919 |

| Number of polypharmacy [1] | | | | | |
|---|---|---|---|---|---|
| 1 [2] | 238 (5.93) | *Reference* | | *Reference* | |
| 2 | 2,632 (65.54) | 4236052.69 (NA) | 0.971 | 8662803.38 (NA) | 0.980 |
| 3 | 1,008 (25.10) | 4778875.76 (NA) | 0.971 | 8500802.01 (NA) | 0.980 |
| 4 | 131 (3.26) | 4589237.83 (NA) | 0.971 | 6546500.33 (NA) | 0.981 |
| 5 | 7 (0.17) | 46259517.35 (NA) | 0.967 | 44983514.65 (NA) | 0.978 |
| Number of comorbidities [3] | | | | | |
| None | 2,558 (63.70) | *Reference* | | *Reference* | |
| 1 | 1,097 (27.32) | 2.54 (1.75 – 3.69) *** | < 0.001 | 1.50 (1.01 – 2.22) * | < 0.05 |
| 2 | 333 (8.29) | 2.70 (1.55 – 4.53) *** | < 0.001 | 1.41 (0.78 – 2.48) | 0.241 |
| ≥ 3 | 28 (0.70) | 12.19 (4.35 – 29.52) *** | < 0.001 | 7.03 (2.27 – 18.97) *** | < 0.001 |

[1] The categories for polypharmacy included anti-diabetic drugs, anti-hypertensive drugs, anti-coagulant drugs and other drugs;

[2] The number of polypharmacy = 1 are the people who are only on statins;

[3] The categories for comorbidities included diabetes, hypertension, chronic respiratory disease, cancer, stroke, blood clots and Parkinson's

disease;

ATSI: Aboriginals and Torres Strait Islanders; SEIFA IRSAD: Socio-Economic Indexes for Areas Index of Relative Socio-Economic Advantage

and Disadvantage; CI: Confidence interval; NA: Not Applicable

## 3.4  Sensitivity analysis

The logistic regression of the model met all key assumptions. **Supplement 3** shows the components of the regression model and their explanations. Overall, the model satisfies all assumptions of logistic regression. The model fits well (Hosmer-Lemeshow test: $p = 0.2245$) and has good discriminative ability (AUC = 0.7921). The details on the assumptions of the regression model are shown in **Supplement 4**.

For the sensitivity analysis, stepAIC model selection procedure was used to remove selected predictor variables from the regression model to produce a parsimonious well-fitted reduced model **(Table 3)**. The estimates are shown in **Supplements 5 and 6**. A similar direction of associations was seen for the exposures of the reduced model and the regression model. However, the reduced model was slightly simpler and fit almost as well as the regression model. The addition of extra predictors in the regression model did not significantly improve the model fit or discriminatory power. As such, the reduced model may be preferred. **Supplement 3** also shows the components of the reduced model and their explanations.

**Table 3:** Sensitivity analysis

| Factors | n (%) | Adjusted Odds ratio (95% CI) | p-value |
|---|---|---|---|
| *Socio-economic and demographic factors* | | | |
| Age (years) | | | |
| ≤ 65 | 2883 (71.79) | *Reference* | |
| > 65 | 1133 (28.21) | 1.32 (0.90 – 1.92) | 0.152 |
| Gender | | | |
| Male | 2,023 (50.37) | *Reference* | |
| Female | 1,990 (49.55) | 1.35 (0.95 – 1.94) | 0.099 |
| Other | 3 (0.07) | 39.92 (1.47 – 1085.97) * | < 0.05 |
| Ethnicity | | | |
| Non-ATSI | 3,038 (75.65) | *Reference* | |
| ATSI | 36 (0.90) | 0.00 (NA) | 0.988 |
| Not recorded | 942 (23.46) | 0.60 (0.31 – 1.07) | 0.102 |
| SEIFA IRSAD category (decile) | | | |
| 1 | 726 (18.08) | *Reference* | |
| 2 | 407 (10.13) | 0.56 (0.16 – 1.53) | 0.301 |
| 3 | 607 (15.11) | 0.24 (0.04 – 0.96) | 0.075 |
| 4 | 1,073 (26.72) | 1.18 (0.65 – 2.20) | 0.590 |

| | | | |
|---|---|---|---|
| 8 | 1,202 (29.93) | 3.83 (2.30 – 6.73) *** | < 0.001 |
| 9 | 1 (0.02) | 0.00 (N/A) | 0.998 |
| Employment status | | | |
| Unemployed | 264 (6.57) | *Reference* | |
| Employed | 697 (17.36) | 1.07 (0.44 – 2.83) | 0.877 |
| Retired and/or pensioner | 568 (14.14) | 2.03 (0.91 – 5.08) | 0.103 |
| Not recorded | 2,487 (61.93) | 2.20 (1.05 – 5.30) | 0.054 |
| ***Statin related factors*** | | | |
| Number of polypharmacy | | | |
| 1 | 238 (5.93) | *Reference* | |
| 2 | 2,632 (65.54) | 3245196.10 (NA) | 0.970 |
| 3 | 1,008 (25.10) | 3191698.87 (NA) | 0.970 |
| 4 | 131 (3.26) | 2652161.18 (NA) | 0.970 |
| 5 | 7 (0.17) | 17718365.55 (NA) | 0.967 |
| Number of comorbidities | | | |
| None | 2,558 (63.70) | *Reference* | |
| 1 | 1,097 (27.32) | 1.51 (1.02 – 2.24) * | < 0.05 |
| 2 | 333 (8.29) | 1.39 (0.77 – 2.43) | 0.258 |
| 3 | 28 (0.70) | 7.38 (2.40 – 19.59) *** | < 0.001 |

[1] The categories for polypharmacy included anti-diabetic drugs, anti-hypertensive drugs, anti-
coagulant drugs and other drugs;
[2] The number of polypharmacy = 1 are the people who are only on statins;
[3] The categories for comorbidities included diabetes, hypertension, chronic respiratory
disease, cancer, stroke, blood clots and Parkinson's disease;
* $p < 0.05$;      ** $p < 0.01$;      *** $p < 0.001$;

ATSI: Aboriginals and Torres Strait Islanders; SEIFA IRSAD: Socio-Economic Indexes for

Areas Index of Relative Socio-Economic Advantage and Disadvantage; CI: Confidence

interval; NA: Not Applicable;

## 4. Discussion

In this study we found that about 3.49% of the patients were statin intolerant in the ePBRN dataset, which is lower than the prevalence of statin intolerance found in Australia (5–15% of patients) (4, 5). The global and Australian estimates of statin intolerance vary greatly due to the various definitions of statin intolerance (6). However, internationally as well as in Australia statin intolerance generally refers to symptoms of adverse effects caused due to statins or SAMS. It also refers to the inability to maintain statin therapy at guideline-directed doses even after rechallenge attempts (37). The estimates also depend on the differentiation between complete and partial statin intolerance, as well as the different thresholds for CK (4, 5, 38). The low estimate of statin intolerance in the ePBRN dataset could be due to several factors such as the patient selection criteria (11). In this study, only RACGP active patients were included, which may have led to the exclusion of some intolerant patients who experienced the symptoms and stopped the medication directly without consulting the GP or patients who returned after the two years of observation period.

This study found that gender, area-based social advantage and disadvantage index, and comorbidities were positively associated with statin intolerance. Several studies reported that compared to males, females are more associated with higher rates of statin intolerance or SAMS, possibly because of the differences in muscle physiology, hormonal factors and/or comorbidity profiles (7, 9, 19, 39). This aligns with the findings of this study where females were also found to be more associated with statin intolerance compared to males. However, such findings are variable and may depend on the population, study design, and definitions. The heterogeneity in the findings highlights the need for a standardized statin intolerance phenotyping algorithm in the EHR system. Literature suggest that statin intolerance is multifactorial, and several other sociodemographic factors can also influence the reporting, diagnosis, estimation, and management (9, 19). While socioeconomic status (SES) indexes are not universally considered as predictor of statin intolerance, although researchers generally found that lower SES areas are associated with higher statin intolerance rates and vice versa (37). Such findings are usually found because of the reduced access to healthcare services and higher burden of comorbidities amongst patients from lower SES and the higher health literacy rate and more proactive reporting amongst those from the higher SES (37). However, contradicting such findings, this study found that patients from relatively advantaged area (SEIFA IRSAD category 8) had 280% higher odds of intolerance, compared

to patients from more disadvantaged areas (SEIFA IRSAD category 1). Studies also show that

higher comorbidity counts can result in higher likelihood of symptoms of intolerance (40).

Moreover, employment status was also found to be positively associated with statin

intolerance in this study. However, similar to smoking status, the association was found

between unrecorded employment status and intolerance, which reflects differences in

healthcare engagement or documentation practices, and the results may be influenced by

residual confounding or information bias which is inherent to EHR data.

## Limitations

This study used the prescription data in the ePBRN Linked Dataset from general practice

facilities, and the study cohort was limited to primary prevention. The focus of this study is

statin intolerance, which lacks a standardized taxonomy and has various definitions, making

it a complex subject. This data included some unrecorded information, that is inherent to the

EHR system, and the unrecorded smoking and employment status cannot be interpreted as a

biological effect since it represents missing clinical information rather than a true exposure.

Sensitivity analysis showed that the predictors of statin intolerance were consistent with the

regression model, supporting the robustness of the findings. However, only a single data

source (ePBRN dataset) was used, and the incomplete recording of sociodemographic

variables affect the generalizability of the findings, since the population characteristics may

differ in other regions. Moreover, the generalizability is further limited as the selection of

patients included those without CVD events before the index date or during the first 2 years

after the index date. This may introduce selection bias by excluding patients at higher short-

term CVD risk.

## 5.  CONCLUSION

This study used the ePBRN dataset from South-western Sydney. It was found that 3.5% of

the patients were statin intolerance. Patients who were females, those from SIEFA index 8,

those who did not have any recorded employment status, and those with 3 or more

comorbidities beside CVDs had about 50%, 280%, 140%, and 600% higher odds of statin

intolerance, respectively, compared to those who were males, from SIEFA index 1,

unemployed, and those with no comorbidities, respectively. Therefore, intolerance to statins

within the diverse community represented in the dataset is driven by gender, employment

status, area-based social advantage and disadvantage index, and comorbidities. The results

obtained in this study may not be fully generalizable, and the generalizability could be tested

different populations and contexts. However, since the unrecorded employment status showed

a positive association, the sensitivity analysis suggests that the relationship between statin

intolerance and employment status may be influenced by residual confounding or information

bias, indicating that this finding should be interpreted with caution.

**Author contributions:**

1. SR and JJ contributed to the conceptualization of this study.
2. JJ contributed to the funding acquisition
3. JR, KAR, STL and JJ contributed to the resources and supervision of this study
4. JR, KAR, STL and JJ contributed to the validation
5. All authors contributed to the reviewing and editing of this study
6. SR and JJ contributed to data curation
7. SR contributed to the formal analysis and the original drafting of this study
8. SR contributed to the methodology of the study

**Data sharing statement:** The corresponding author will make the data available upon request.

**Competing Interests:** Joel Rhee has received honorarium from Merck Sharpe & Dohme and Pfizer for providing advice, chairing and presenting at educational events for clinicians. Jitendra Jonnagaddala has served in a consulting or advisory capacity for WHO and UNICEF and he also received speakers' fees from the Ministry of Health, Indonesia. The Authors declare that they have no other competing interests.

**Funding:** This study was funded by the Australian National Health and Medical Research Council (Grant Number: GNT1192469). JJ also acknowledges the funding support received through the 296 Research Technology Services at UNSW Sydney, Google Cloud Research (Award Number: 297 GCP19980904), and the NVIDIA Academic Hardware grant programs.

**Acknowledgements:** We would like to thank the ePBRN Primary Care Health Informatics Working Group of the Secure Research Environment for Digital Health (SREDH) Consortium (www.sredhconsortium.org, accessed on 7 October 2024) for their assistance with access to the ePBRN dataset to investigate the findings from this review.

# References

**References**

1.  Talic S, Hernandez CM, Ofori-Asenso R, Liew D, Owen A, Petrova M, et al. Trends in
the utilization of lipid-lowering medications in Australia: an analysis of national
pharmacy claims data. Current Problems in Cardiology. 2022;47(7):100880.

2.  MedicineWise NPS. Statins revisited–appropriate patient selection and management are
key.

3.  Hilmer S, Gnjidic D. Statins in older adults. Australian Prescriber. 2013;36(3).

4.  Fitchett DH, Hegele RA, Verma S. Statin intolerance. Circulation. 2015;131(13):e389-
e91.

5.  Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, et al. Management of
statin intolerance in 2018: still more questions than answers. American Journal of
Cardiovascular Drugs. 2018;18:157-73.

6.  Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin
intolerance–an attempt at a unified definition. Position paper from an International
Lipid Expert Panel: This paper is also published in parallel in Archives of Medical
Science [Banach M, Rizzo M, Toth PP, et al. Statin intolerance–an attempt at a unified
definition. Position paper from an International Lipid Expert Panel. Arch Med Sci
2015; 11 (1): 1–23]. Expert opinion on drug safety. 2015;14(6):935-55.

7.  Alonso R, Cuevas A, Cafferata A. Diagnosis and management of statin intolerance.
Journal of atherosclerosis and thrombosis. 2019;26(3):207-15.

8.  Raju SB, Varghese K, Madhu K. Management of statin intolerance. Indian journal of
endocrinology and metabolism. 2013;17(6):977.

9.  Bytyçi I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al.
Prevalence of statin intolerance: a meta-analysis. European heart journal.
2022;43(34):3213-23.

10.  Llanes EJB, Thongtang N, Lee Z-V, Hoa T, Yee OH, Sukmawan R. Addressing
adherence challenges in long-term statin treatment among Asian populations: Current
gaps and proposed solutions. American Journal of Preventive Cardiology.
2025:101019.

11.  Warden BA, Guyton JR, Kovacs AC, Durham JA, Jones LK, Dixon DL, et al.
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical
perspective from the National Lipid Association. Journal of clinical lipidology.
2023;17(1):19-39.

12.  Stulc T, Ceška R, Gotto Jr AM. Statin intolerance: the clinician's perspective. Current
atherosclerosis reports. 2015;17(12):69.

13.  MedicineWise N. Uncovering the truth about statin intolerance 2017 [Available from:
https://www.nps.org.au/news/uncovering-the-truth-about-statin-intolerance.

14.  K Siddiqui M, Maroteau C, Veluchamy A, Tornio A, Tavendale R, Carr F, et al. A
common missense variant of LILRB5 is associated with statin intolerance and myalgia.
European heart journal. 2017;38(48):3569-75.

15.  Petrkova J, Taborsky M, Petrek M. Pharmacogenetics of Cardiovascular Disease:
Genetic. Genetic Diversity and Disease Susceptibility. 2018:127.

16.  Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of
pharmacokinetic, pharmacogenomic and muscle components. Journal of clinical
medicine. 2019;9(1):22.

17.  Curfman G. Statin-associated myopathy—an elusive clinical problem. JAMA Internal
Medicine. 2018;178(9):1230-.

18.  Lichtenstein KA, Hart RL, Wood KC, Bozzette S, Buchacz K, Brooks JT, et al. Statin
use is associated with incident diabetes mellitus among patients in the HIV outpatient
study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2015;69(3):306-11.

19.  Penson PE, Bruckert E, Marais D, Reiner Ž, Pirro M, Sahebkar A, et al. Step□by□step
diagnosis and management of the nocebo/drucebo effect in statin□associated muscle

symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).
Journal of cachexia, sarcopenia and muscle. 2022;13(3):1596-622.

20.  Penson PE, Banach M. Nocebo/drucebo effect in statin-intolerant patients: an attempt at
recommendations. Oxford University Press; 2021.

21.  Banach M, Penson PE. Drucebo effect–the challenge we should all definitely face!
Archives of Medical Science: AMS. 2021;17(2):542.

22.  Khan S, Holbrook A, Shah BR. Does Googling lead to statin intolerance? International
Journal of Cardiology. 2018;262:25-7.

23.  Penson PE, Mancini GJ, Toth PP, Martin SS, Watts GF, Sahebkar A, et al. Introducing
the 'Drucebo'effect in statin therapy: a systematic review of studies comparing reported
rates of statin☐associated muscle symptoms, under blinded and open☐label conditions.
Journal of Cachexia, Sarcopenia and Muscle. 2018;9(6):1023-33.

24.  Martirossian AN, Goldberg AC. Management of patients with statin intolerance. Best
Practice & Research Clinical Endocrinology & Metabolism. 2023;37(3):101714.

25.  Spitz J, Patel J, Agarwala A, Sharma G, Mehta A, Natarajan P, et al. A Critical
Appraisal of Lipid Management in the Post-Statin Era: Comparison on Guidelines,
Therapeutic Targets, and Screening in a Case-Based Framework of Lipid Management.
JACC: Advances. 2025;4(6_Part_2):101823.

26.  Elias S, Chen Y, Liu X, Slone S, Turkson-Ocran R-A, Ogungbe B, et al. Shared
decision-making in cardiovascular risk factor management: a systematic review and
meta-analysis. JAMA network open. 2024;7(3):e243779-e.

27.  Secure Research Environment for Digital Health SREDH. ePBRN 2019 GP + Hospital
linked Dataset 2024 [Available from: https://www.sredhconsortium.org/sredh-
datasets/epbrn-2019-gp-hospital-linked-dataset.

28.  Kadappu P, Jonnagaddala J, Liaw S-T, Cochran BJ, Rye K-A, Ong KL. Statin
prescription patterns and associations with subclinical inflammation. Medicina.
2022;58(8):1096.

29.  Seaman K, Sanfilippo F, Bulsara M, Roughead L, Kemp-Casey A, Bulsara C, et al.
Predictors of ceasing or reducing statin medication following a large increase in the
consumer copayment for medications: a retrospective observational study. Public
Health Research and Practice. 2020;30(1).

30.  Ofori Asenso R, Ilomaeki J, Tacey M, Si S, Curtis AJ, Zomer E, et al. Predictors of
first year nonadherence and discontinuation of statins among older adults: a
retrospective cohort study. British journal of clinical pharmacology. 2019;85(1):227-35.

31.  Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical
prediction modelling. Family medicine and community health. 2020;8(1):e000262.

32.  Barton RR, Rhodes-Leader LA, editors. Bootstrap Confidence Intervals for Simulation
Output Parameters. 2023 Winter Simulation Conference (WSC); 2023: IEEE.

33.  Farag KA, Asselhab MA, Binsoud BM, Abobaker ZM. Performance Comparison of
Traditional Bootstrap and Bias-Corrected and Accelerated Methods in Constructing
Confidence Intervals for Non-Normal Data: A Simulation Study. Libyan Journal of
Medical and Applied Sciences. 2025:115-20.

34.  Chung TK, Jeon Y, Hong Y, Hong S, Moon JS, Lee H. Factors affecting the changes in
antihypertensive medications in patients with hypertension. Frontiers in Cardiovascular
Medicine. 2022;9:999548.

35.  Bauer T, Höfer H, Schirmel J. Dry grasslands in urban areas can harbour arthropod
species of local conservation concern and should be prioritised for
biodiversity friendly mowing regimes. Insect Conservation and Diversity.
2024;17(5):811-25.

36.  Riley P, Riley A, Turtle J, Ben-Nun M. COVID-19 deaths: Which explanatory
variables matter the most? Plos one. 2022;17(4):e0266330.

37.  Sivashanmugarajah A, Fulcher J, Sullivan D, Elam M, Jenkins A, Keech A. Suggested
clinical approach for the diagnosis and management of 'statin intolerance'with an
emphasis on muscle related side effects. Internal medicine journal. 2019;49(9):1081-
91.

38.  Parhofer KG, Anastassopoulou A, Calver H, Becker C, Rathore AS, Dave R, et al.
Estimating prevalence and characteristics of statin intolerance among high and very
high cardiovascular risk patients in Germany (2017 to 2020). Journal of Clinical
Medicine. 2023;12(2):705.

39.  Bair TL, May HT, Knowlton KU, Anderson JL, Lappe DL, Muhlestein JB. Predictors
of statin intolerance in patients with a new diagnosis of atherosclerotic cardiovascular
disease within a large integrated health care institution: the IMPRES study. Journal of
cardiovascular pharmacology. 2020;75(5):426-31.

40.  Rosenson R, Baker S, Jacobson T. Uncovering the truth about statin intolerance. 2017.

**Figure 1:** Overview of the identification of statin intolerant patients

CK: Creatine kinase

* The threshold for creatine kinase (CK) was different for patients with and without muscle symptoms

**Figure 2:** Selection of eligible patients